BridgeBio says FDA reviews NDA for infigratinib in achondroplasia

PUBT · 2d ago
BridgeBio says FDA reviews NDA for infigratinib in achondroplasia
  • BridgeBio submitted a U.S. FDA NDA for oral infigratinib to treat achondroplasia.
  • Company targets a U.S. launch in mid-2027, pending FDA review.
  • EMA marketing application filing expected in Q4 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609090400PRIMZONEFULLFEED9823248) on September 09, 2026, and is solely responsible for the information contained therein.